Exhalation Delivery System: Novel Device for Nasal Polyps Treatment

Area of Science:

• Otolaryngology
• Respiratory Medicine
• Drug Delivery Systems

Background:

• Nasal polyps affect both adults and children, often requiring glucocorticoid treatment.
• Current topical and systemic glucocorticoid therapies can be ineffective, leading to refractory nasal polyps.
• Existing nasal drug delivery methods face challenges with patient coordination and poor lung deposition.

Purpose of the Study:

• To introduce and evaluate an innovative exhalation delivery system for nasal polyp treatment.
• To address the limitations of conventional nasal drug delivery systems.
• To assess the efficacy of Xhance (fluticasone propionate) in treating nasal polyps.

Main Methods:

• Development of an exhalation delivery system by Optinose for liquid and powdered medications.
• Utilizing Xhance (fluticasone propionate) with the novel delivery system.
• Clinical evaluation in adult patients and ongoing trials in pediatric populations.

Main Results:

• The exhalation delivery system demonstrates potential for improved medication delivery to the nasal cavity.
• Xhance has shown promising results in adult patients with nasal polyps.
• The system aims to overcome challenges related to patient coordination and lung deposition.

Conclusions:

• The Optinose exhalation delivery system represents a significant advancement in nasal drug delivery.
• Xhance offers a potentially more effective treatment option for nasal polyps in adults.
• Further evaluation in pediatric patients is underway to broaden treatment accessibility.